Cardiac transplantation displays a well established therapeutic procedure for different end-stage heart diseases. Effective immunosuppressive drugs, progress in operative techniques, modern perioperative intensive care, and application of increasingly potent antibiotics in case of postoperative infections led to an improvement in short term outcome of organ transplantation. Nevertheless, achievements in long term transplant results are rare due to rejection of allografts. Chronic graft rejection is the major cause of late transplant failure.
According to present knowledge, T cells, infiltrating monocytes and macrophages, and NK cells, respectively, are involved in acute and chronic rejection. Numerous clinical trials and investigations in animal or cell culture models point out, that cell adhesion molecules, cytokines, and chemokines play a decisive role in the acute and chronic rejection of solid organ grafts.
Heterotopic cardiac transplantation in mice is considered to be the best model to study immunological mechanisms of transplant rejection. This technique allows the analysis of rejection processes in different mouse strains with defined genetic defects. Thus, distinct immunological receptors and ligands can be scrutinized for their impact on physiological and pathophysiological mechanisms of acute and chronic graft rejection. Results achieved from this model could be transferred to human beings in the majority of cases. As such, the model of heterotopic cardiac transplantation in mice has the potential to discover new therapeutic strategies which can be transferred to the clinic.
The aim of this chapter is to present our comprehensive microsurgical expertise on this model to other research groups in the field of cardiac transplantation. It delineates the practicable microsurgical model of heterotopic cardiac transplantation in mice as performed in our centre, based on the initially presented technique nearly four decades ago. Furthermore, the necessity of this
2. History and clinical-experimental development of transplantation
Basic requirement for transplantation of vascularized organs was the development of surgical vascular anastomosis techniques, crucially brought forward by Alexis Carrel in Lyon, France at the beginning of the last century [Carrel & Guthrie, 1905]. He successfully performed numerous heart transplantations in dogs and received the Nobel Prize for his research in 1912. In the year 1954 Joseph Murray (Boston, USA) performed the first successful solid organ transplantation in human beings in terms of the first kidney transplantation between monocygotic twins [Merrill et al., 1956]. In 1963 both Starzl (Denver, USA) and Hardy (Mississippi, USA) performed the first liver transplantation and lung transplantation, respectively. The first pancreas transplantation was realized by Richard Lillehei (Minnesota, USA) in 1966 and finally Christian Barnard (Cape Town, South Africa) performed the first human heart transplantation in 1967.
The knowledge about transplant immunology is derived from basic experimental findings during transplantation in animal models. Cellular principles of organ rejection were conclusively described by the English biologist Peter Medawar, who received the Nobel Prize for the “discovery of immunological tolerance“ in 1960 [Billingham et al., 1951]. In 1953, histocompatibility antigen was reported for the first time on the surface of leucocytes. Jean Dausset therewith established the basis for histological typing between donor and recipient which is nowadays routinely performed within the pre-operative screening previous to each transplantation, the so-called HLA matching (testing of congruousness of those genes that are responsible for transplant rejection). Nevertheless, T cell mediated immune defence against the graft is not covered in these investigations though T cells take up a key function in transplant rejection [Sayegh & Carpenter, 2004]. This T cell reactivity could be accurately examined in our transplant centre in living donor kidney transplantation between monocygotic twins and in consequence immunosuppression was first reduced and then completely withdrawn [Hüser et al., 2009]. To date, medication free development of tolerance or at least reduction of required immunosuppressive drugs remains to be the unchanged goal for increased postoperative transplant survival.
Of course, transplantation of organs between genetically identical individuals continues to be exceptional as transplantation is usually performed in an allogeneic context which implicates the risk of an acute rejection episode. Technical advance and improvements in medicamentous therapy by implementation of potent immunosuppressants lead to an over-all one-year graft survival of more than 80% [Christie et al., 2010]. On the other hand, no relevant enhancements in long-term outcome of grafts could be determined. Chronic transplant rejection is hereby the main reason for late graft failure. Besides non-immunological donor- and recipient-dependent factors, mainly immunological reactions represent an important role for graft survival. Heterotopic heart transplantation in mice provides an important and valid model for analysis of immunological events during acute and chronic rejection mechanisms.
3. Necessity of an
in vivo model for investigation of immunological events mediating organ rejection
The reaction against an allograft is composed of a complex cascade of immunological processes and some parts of them can be analyzed
A technique utilizing the transplantation of a non vascularized heart was established by Fulmer and coworkers, where neonatal murine cardiac tissue was placed subcutaneously into the pinna of the recipients ear [Fulmer et al., 1963]. Using this technique certain aspects of acute rejection have been studied. Nevertheless, the factors that lead to cardiac allograft vasculopathy all interact within the transplanted vessels at the blood / endothelial interface, making a vascularized cardiac transplant model imperative for the studies of chronic graft rejection [Hasagewa et al., 2007]. Other research groups refer to a simplified and technically easier model of vascularized transplantation in which the graft is anastomosed to the cervical vessels [Chen, 1991; Tomita et al., 1997]. However, according to Doenst et al., first, the positioning of the transplanted heart in an infrarenal position is self-guided and less likely to allow torsion, and second, the carotid artery is smaller in diameter than the ascending aorta of the donor, what makes the aorto-aortic anastomosis easier to perform [Doenst et al., 2001]. Finally the decision of which operative procedure is performed depends on the personal preference.
4. Anatomical specialities of the heterotopic heart transplantation model
The harvested donor heart is transplanted heterotopically by performing vascular anastomoses of the aorta and the pulmonary artery to the large infrarenal vessels of the recipient [Corry et al., 1973]. Therefore, the recipient mouse is not dependent on the functioning of the graft as its own heart remains untouched and the mouse undergoes rejection of the graft without impairment of physical well-being. A difference of this method compared to orthotopic heart transplantation is related to the technique of vessel anastomoses. The ascending aorta (AscA) of the donor heart is anastomosed end-to-side to the abdominal aorta (AbdA) and the pulmonary artery (PA) is anastomosed end-to-side to the recipient’s inferior vena cava (IVC). This leads to a retrograde blood flow from the abdominal aorta via the ascending aorta directly into the coronary arteries whilst bypassing the left ventricle (LV) and left atrium (LA). After a while a thrombus accrues in the left ventricle. Hence, the oxygen supply of the heart muscle is hereby ensured by the capillary bed. Coming from the coronary arteries, the blood flow then passes the coronary veins and next converges in the coronary sinus (CS) and the right atrium (RA). From the right atrium the blood courses to the right ventricle (RV) and using the stump of the pulmonary trunk it finally reaches the recipients IVC (see fig. 1 ). The presented model is a so-called „non working heart model“, because the graft does neither maintain physiological cardiac output nor pump against physiological pressure.
5. Options of rejection diagnostics after heterotopic heart transplantation
A relevant advantage of this operative method is the efficient rejection diagnostic of the transplanted heart. An algorithm on investigative technique could be developed to guarantee both the most comfortable examination for the transplanted mouse and the complete and comprehensive acquisition of acute and chronic rejection.
Finger palpation of the transplanted heart is a sensitive method to appraise time-dependent course of rejection. Concerning the contraction power and the induration of the graft, respectively, different stages can be graduated [Schmid et al., 1994]. In case of applying too high pressure, the graft cannot fill up and fully pulsate, and contractility is underestimated [Martins, 2008]. In the hand of an experienced diagnostician, slightest differences, especially the rapidly decreasing contraction power during acute rejection can be measured. In diagnostics of chronic transplant failure, evaluation occasionally might be difficult due to successive impairment of cardial pump functioning, as heart pulsation is directly related to the amount of intact myocard.
The validity of supplementary analysis to get the exact rejection time point remains controversial. Performance of electrocardiogram (ECG) requires exact subcutaneous placement of needle electrodes [Superina et al., 1986], validity is heavily dependent on the organ’s position and movement [Mottram et al., 1988], and therefore the utility of this method is limited. In acute rejection, frequency shows rapid decrease in combination with various ECG alterations [Babuty et al., 1996]. In literature, magnetic resonance imaging is described as an additional tool in diagnostics for assessment of transplanted hearts. Nevertheless, this expensive procedure should be reserved for specific settings only. Moreover, in perfusion studies of solid grafts, results revealed to be extremely dependent on length and depth of narcosis [Wu et al., 2004]. Recent investigations describe high-frequency ultrasound biomicroscopy modality besides conventional echocardiography, a new non-invasive imaging method for diagnostic of acute rejection [Bishya, 2011]. Various papers report on a decrease of end-diastolic diameter and an increase of left ventricular posterior wall thickness, respectively, to be parameters of acute rejection. However, changes in left ventricular posterior wall thickness, seem to be increasingly difficult to measure after the fifth post-operative day, which points to the limitation of the use of echocardiogram in diagnosing acute allograft rejection [Scherrer-Crosbie et al., 2002]. In principle, every final rejection, either acute or chronic, has to be confirmed by diagnostic laparotomy to avoid misjudging passive movement of the graft by transmission of the aortic pulsation as graft beating.
6. The method of heterotopic heart transplantation in mice
The model of heterotopic heart transplantation in mice has been varied manifoldly since its first description by Robert Corry and Paul S. Russell in 1973 [Mao et al., 2009; Wang et al., 2005; Hasegawa et al., 2007]. The following chapter describes the transplantation procedure and incorporates our experience using an operating microscope (OPMI-6, Carl Zeiss, Jena, Germany) and a magnification between 4x-20x objective. Operation time is approximately 45 minutes and peri-operative mortality in the hands of an experienced micro-surgeon is less than 5%.
6.1. Anaesthesia and analgesia
All operative procedures in animals are performed using Isoflurane narcosis (Forene with 1-Chloro-2,2,2-trifluoroethyl-difluoromethylether). Both donor and recipient mouse can be operated under pain-free, unconscious, and relaxed conditions. Isoflurane narcosis brings along the crucial advantage of easy handling and having almost no influence on the animal’s blood pressure in contrast to other narcotics such as e.g. Ketanest. Furthermore, Isoflurane narcosis is the least hepatotoxic narcotic drug. Basal anaesthesia is performed with 5% Isoflurane and for maintainance approximately 2% Isoflurane are necessary. Endotracheal anaesthesia is not necessary. Animals reliably wake up approximately 10 min after the end of narcosis.
6.2. Donor operation and preparation
The mouse intended for donor operation receives narcosis in the above mentioned way. Afterwards, the mouse which lies on its back gets fixed with tape at its limbs to a corkboard and Isoflurane is applied via a tube to the mouse’s nose. Hereby, interim awakening of the animal can be avoided.
The operation starts with median laparotomy. The abdomen is kept open by use of two needles, fixing the peritoneum to the corkboard. The bowel gets enveloped into a moist compress and put away to the right side outside the mouse. Then the IVC and the abdominal aorta can be prepared with a cotton swab. Using 1 ml syringe and 25G needle, the Aorta is canulated and as much blood as possible is aspirated. The initially performed abdominal cut to the lower margin of the left hepatic lobe has to be extended to the sternum. Next, two more cuts have to be done along the costal arches to enable separation of the diaphragm from its costal and sternal adherence. In the following step the thorax is opened by cutting along the midaxillary line right up to the upper thorax aperture. Fixation of the sternum above the mouse’s head (e.g. with a needle holder) guarantees free access to the opened thoracic cavity. Via puncture of the IVC the heart can now be flushed with cardioplegic fluid and it stops beating. After preparation and resection of the thymus gland, the inferior vena cava and the superior vena cava (SVC) are ligated with 6/0 silk. Silk ties are placed around the right and left pulmonary vessels (RPV / LPV) to exclude the lungs. Finally, the azygos vein (AV) is ligated. The donor heart is gently detached from the surrounding tissue with blunt dissection. For anastomosis of the recipient`s abdominal aorta (AbdA) the donor`s Aorta ascendens (AscA) and pulmonary artery (PA) remain open (see fig. 2 ). By now the heart can be harvested by sharply dividing along the esophagus and cutting the ligated vessels. The ascending aorta is cut below the brachiocephalic artery and the main pulmonary artery is cut proximal to its bifurcation.
Preparation of the pulmonary trunk and the Pars ascendens aortae has to be performed ex situ. Both of them are piggybacked on a curved pair of pincers and cut with a micro-surgical pair of scissors. Hereby you get two homogeneous and relatively long vessel stumps that enable easy implantation during the recipient operation. Until this moment the cardiac graft has to be stored in 4 C cold cardioplegic solution (e.g. Bretschneider’s cardioplegic solution, Köhler Chemie, Alsbach, Germany).
6.3. Recipient preparation and transplantation
For the recipient operation narcosis, fixation on the corkboard, and median laparotomy from the symphysis to the lower margin of the left hepatic lobe are performed as described above during the donor operation. After opening the abdominal cavity and fixation of the peritoneum with two needles (alternatively a self-retaining retractor can be used) the bowel is enveloped into a moist compress and put away to the right side outside the mouse.
Repetitive soaking of the compress with sterile saline guarantees a humid environment for the bowel during the entire procedure. The retroperitoneal space can be opened easily by gentle rotary motions with two cotton swabs. An additional cotton swab fixed in a needle holder can be used for permanent dislocation of the sigma and the left kidney outside the operating area after dividing the meso-sigmoid. Now the large vessels – Aorta abdominalis and IVC – are accessible and have to be separated from surrounding fatty tissue and adjacent lymph nodes. The preparation of the vessels starts directly below the outlet of the renal arteries and has to be performed to the aortic bifurcation. In case of lumbal veins in this segment, they have to be exposed and coagulated to assure that both the aorta and the IVC lie unfettered. Two vessel clamps have to be positioned at the ends of the prepared segment, respectively, to interrupt the flow in both the aorta and the IVC. The distal clamp has to be put first, to assure partially filled vessels for aortotomy and venotomy in the next step (see fig.3 ).
In the following step, the aorta has to be opened by a short longitudinal section using micro-scissors. This can be done easily without prior arteriotomy by a 25 or 30 gauge needle and is extended to a length of equal to the donor´s ascending aorta. After flushing the vascular lumen with saline, an end-to-side anastomosis of the pars ascendens aortae of the cardiac graft and the abdominal aorta has to be performed. The silk thread that has been left long at the IVC during the donor operation can now be inserted in a small clamp and therefore helps to move the heart without any injuring touch into the right position in relation to the recipient’s vessels. Two stitches in the edges with a 10/0 monofil thread fix together the donor’s and the recipient’s aorta. The graft is shifted to the right inferior abdomen of the mouse to facilitate free access to the left lateral side of the aorta. Now the first continuous suture can be performed by means of 4 stitches. For the knot we use the thread of the opposite edge stitch (see figure 4a) . At this time point the donor heart is flipped from the right side of the mouse to the left using the long thread at the IVC.
The corkboard can now be half-turned, so the vessel’s ”back wall“ becomes ”front wall“ and the suture is performed accordingly with 4 stitches (see
. Finally, after knotting, the threads have to be cut to a length of approximately 2 mm. The next step is the venotomy. The incision with the micro scissors is performed just as the aortic incision and proportionately to the lumen of the pulmonary trunk of the donor. Again two edge stitches have to be done. Hereby it is important to fix the ”back wall“ with slightly more tension compared to the ”front wall“ to obtain best possible exposition of the operation area. This is due to the fact, that the end-to-side anastomosis of the opened IVC and the pulmonary artery of the donor has to be closed with a running suture in the inside of the IVC. For this purpose the suture must be stitched from the outside to the inside of the vessel lumen at the beginning and vice versa at the end of the suture before the knot can be done outside the lumen. For the continuous suture again 4 stitches are necessary (se
After the knot with the proximal suture, the right wall of the IVC and the pulmonary artery of the donor are closed with another 5 stitches of a continuous suture outside the IVC. After knotting with the thread from the distal edge stitch both threads are cut to a length of approximately 2mm. Finally, the heart can be reperfused by opening the clamps after a cold ischemia period of approximately 25 minutes. The distal clamp is removed first to check the anastomosis of the IVC. Rapid stain towards bright red, refilling of the coronary vessels, and time-displaced beginning of cardiac contractions indicate the successful performance of the operation. After cleaning the heart from residual adjacent tissue particles and repositioning of the bowel into the abdominal cavity, the abdomen is closed by means of a continuous suture of the musculature and the peritoneum, respectively, and completing closure of the skin with single stitches (all using 5/0 monofil non-resorbable thread). Then the Isoflurane leading tube is removed from the animal’s head. Within the next minutes the mouse awakes from narcosis. The recipient’s operation takes approximately 35 minutes. The cage is put under a heating lamp for another 20 minutes and the recipient gets tramadol drops for post-operative analgesia.
7. Potential of heterotopic heart transplantation in mice for elucidating molecular mechanisms of graft rejection
Graduation of rejection after solid organ transplantation is primarily based on histopathological changes. Detection of immunological effector mechanisms display only a minor role in this field and cannot necessarily be correlated to the severity of graft rejection. Hyperacute, acute, and chronic rejections can be discriminated, but the impression must not be created that they are chronologically consecutive phases of rejection. Whereas hyperacute rejection emerges quite rapidly after transplantation, it is entirely possible, that acute and chronic rejection occur simultaneously. Therefore, each rejection episode is designated to a macroscopic and a histopathological image rather than to a concrete point in time (see also fig.5).
The molecular and cellular mechanisms of the innate and the adaptive immune system responsible for acute and chronic graft rejection have been studied in the experimental setting of heterotopic cardiac transplantation in detail. In vertebrates, innate immunity mediates early host defence and comprises inflammatory cells that express receptors detecting conserved pathogen associated molecular patterns (PAMPs). Beside non-cellular mediators capable of microbial recognition (e.g. the complement system) especially natural killer (NK) cells constantly participate in surveillance for intact self by sensing the presence of autologous major histocompatibility complex molecules. In this context we could demonstrate the importance of NK cells during rejection of cardiac transplants. Acute graft rejection includes massive NK and NKT cell infiltration into the transplanted organ. We found that NK and NKT cells, contribute to the activation of alloreactive T cells. Furthermore, inhibition of NK and/or NKT cells in absence of the co-stimulatory receptor CD28 induced long-term acceptance of semi-allogeneic grafts transplanted to CD28-deficient recipients [Maier et al., 2001]. In the same situation, fully allogeneic grafts were rejected in CD28 deficient hosts, although at later time point compared to wild type controls. These findings clearly point out the advantage of the in vivo model of cardiac transplantation allowing to create an either completely or semi-allogeneic constellation between donor and recipient. Importantly, the generation of allogeneic response against grafts involves numerous activation pathways and the impact of single components is often not visible unless this complexity is reduced. Moreover, NK1.1 positive (NK/NKT) cells could not only be assigned to have relevant influence on rejection of cardiac grafts, these data also hint to the important and close interaction between the innate and adaptive immune system.
The advances in immunosuppressive therapy have made severe acute cellular rejection of organ grafts uncommon. This has revealed to the form of acute antibody-mediated rejection – now widely accepted as a distinct clinicopathologic entity [Colvin, 2007] - that is resistant to current immunosuppression and acts through graft rejection by activation of complement, vascular endothelial and smooth muscle cells, and by activation of macrophages, neutrophils or NK cells, respectively [Wehner et al., 2009]. More recent data have highlightened antibody-mediated rejection as a cause for chronic rejection [Colvin, 2007]. A detailed knowledge of the underlying mechanism could provide insights for effective therapeutic interventions, e.g. monoclonal antibodies to C5 [Wang et al., 2007]. However, the use of the murine heart transplant model to determine whether antibodies contribute to the rejection process had only limited success so far [Wehner et al., 2009]. Anatomical differences of the cardiac vascular bed between humans and mice might be a limiting factor in addressing this particular question. In contrast to mice, human coronaries contain vasa vasorum, and coronaries of the murine heart do not pass the surface but rather directly enter the myocardium after their origin. Thus, investigating humoral rejection processes, the model of heterotopic heart transplantation in mice is only applicable to a limited range.
The adaptive immune response as an essential element of the rejection process is mainly characterized by an engagement of T cells. Genetically non-identical transplanted organs display peptides recognizes as foreign to host T cells. Helper T cells of the recipient become activated by foreign peptides that are displayed on antigen presenting cells (APC) in the donor organ. Interaction of activated helper T cells with B cells results in production of antibodies against the graft and activation of other immune cells, e.g. macrophages. In addition, allogen-specific CD8 cytotoxic T cells are known to be important for promoting transplant rejection in humans. This is in line with events during heterotopic allograft rejection in mice where we and others found a predominant activation of CD8 T cells in the transplanted heart of recipients [Hüser et al., 2010; Schnickel et al., 2004]. In vitro both, CD4 and CD8 T cells, proliferate in response to allogeneic stimuli. However, we could not detect activated CD4 T cells within cardiac grafts. In contrast, CD8 T cells were recruited in high numbers into the allograft and showed a phenotype of activated effector T cells [Hüser et al., 2010]. Again this indicates that the in vivo model of heterotopic heart transplantation in mice has great over in vitro studies and closely resembles the events taking place in humans.
Both, B and T lymphocytes use antigen receptor engagement to initiate distinct signal transduction pathways that affect cellular responses. It is well established that adaptor molecules regulate signaling of receptor proximal events inducing gene expression or cytoskeletal rearrangement. Beer et al. identified the putative adaptor protein SLY1, that is preferentially expressed in T and B lymphocytes and is defined as target for antigen receptor signal transduction with an important role in the adaptive immunity. It was shown that SLY mutant mice reveal impaired lymphoid organ development and antigen receptor mediated lymphocyte activation. Using the model of heterotopic cardiac transplantation, we were able to show extended allograft survival. Thus, signaling events mediated by SLY1 protein in cells of the adaptive immune system appear to be of importance for mechanisms inducing transplant rejection [Beer et al., 2005].
Chemokine receptors and their ligands, expressed by responding leukocytes and the inflamed transplant tissue, are responsible for the recruitment of alloreactive immunocytes into the graft. According to Hancock, several important points have emerged so far from murine in vivo transplant studies. (1) Targeting a single chemokine is in most cases ineffective in prolonging allograft survival, (2) chemokine receptors differ in their importance as targets in alloresponses, and (3) effects of concomitant immunosuppression can modulate the outcome of chemokine receptor targeting in otherwise untreated mice [Hancock, 2002]. The innate and adaptive immune reactions are initiated before, at the time of transplantation (e.g. by ischemia-reperfusion injury), and after transplantation by non-immunological and immunological factors, leading to graft vasculopathy with a diffuse narrowing of the coronary arteries and an adventitial fibrosis as common signs of chronic graft rejection. Chronic rejection is the response of the recipient’s organism towards the cumulative injury to the transplanted graft over time, with involvement of cellular and humoral (antibody mediated) components [Chapman et al., 2005]. Best established model of chronic rejection in the mouse is the heterotopic cardiac allograft [Cornell et al., 2008]. On the basis of this in vivo model we could characterize the role of chemokine receptor CCR4 in chronic transplant failure. In accordance with Hancock [Hancock, 2002], absence of CCR4 receptor per se is not sufficient to achieve long-term transplant survival of fully allogeneic donor hearts in CCR4-deficient recipients and only marginal prolongation of heart survival was noticed.
In addition, no significant immunohistological difference in cellular infiltration comparing wild type and CCR4-deficient mice could be observed [Hüser et al., 2005]. In contrast, injection of Gallium nitrate, known to delay graft rejection, resulted in a significantly prolonged persistence of heart action in CCR4-deficient mice compared to wild type controls [Hüser et al., 2005]. These results could be confirmed by findings in CCL17-deficient mice, CCL17 being the specific ligand of CCR4 [Alferink et al., 2003]. Besides constitutively expressed chemokines like CCL19 and CCL21 that mainly recruit naive T cells in the lymph node, inflammatory chemokines like CCL2, CCL3, CCL17 and CCL22 mainly cause accumulation of activated T cells and T memory cells in inflamed organs. Inhibition of several of these chemokines have been shown to be beneficial for graft survival [Tan et al., 2005].
Recruitment of activated lymphocytes into inflamed tissue is of major importance for the control of immune responses. Beside chemokines, the role of the leukocyte integrins in the immunological reactions of organ transplant rejection is essential. The integrin LFA-1 is expressed on all leukocytes as an adhesion molecule and has a significant role not only in lymphocyte migration but also in mediating T cell interaction with APC and consequently T cell priming [Hogg et al., 2003]. Function of LFA-1 is tightly controlled by regulating its activity state [Evans et al., 2009]. Generating a mouse mutant that expresses constitutively active LFA-1 (LFA-1d/d) [Semmrich et al., 2005] we could point out for the first time in vivo the importance of integrin deactivation on immune response inducing allograft rejection [Hüser et al, 2010]. We demonstrated that regulating LFA-1 activity from an active to an inactive state promotes successful activation, clonal expansion, and generation of effector T cells in response to allogeneic stimuli in vivo. Defective LFA-1 deactivation furthermore negatively affects recruitment of all major leukocytes from the innate and the adaptive immune system known to be involved in transplant rejection. By using the model of heterotopic cardiac transplantation we were able to provide direct in vivo evidence that regulating LFA-1 deactivation might be as important as regulating LFA-1 activation for effective immune responses during allograft rejection.
Those examples for studies in gene knock-out and transgenic mice using organ allografts identified the central role of a variety of target cells, chemotactic mediators, signalling components, and adhesion molecules on lymphocytes. As such, the described model of herterotopic cardiac transplantation in mice can be considered as a valid animal model and serves as an important achievement for clinical development of strategies that interfere with immune responses inducing transplant rejection.
Advances in the field of immunosuppression and better understanding of immunological courses in the last years contributed to establish organ transplantation as regularly performed clinical therapy and helped patients with severe renal, hepatic, pulmonary, and cardiac diseases to achieve longer survival and better quality of life. Short-term outcome after organ transplantation is impressive, whereas long-term graft survival remains to display a crucial problem. Induction of donor-specific tolerance towards transplanted tissue remains to bet the aim.
Heterotopic heart transplantation in mice is a vascularized immunological model and the recipient is not dependent on maintenance of circulation and cardiac functioning. As an in vivo model it has been shown to be an ideal compromise between clinical reality and experimental reproducibility of underlying essentials that peak in acute rejection or chronic transplant failure over time, however immunological differences between mice and human beings must be kept in mind. And, if so, mice as an in vivo model of first choice will continue to push forward our immunological understanding of immune reactions in transplantation.
Abbott C. P. Lindsey E. S. Creech O. Jr. Deitt C. W. 1964A technique for heart transplantation in the rat. , 89October 1964), 645-652.
Alferink J. Lieberam I. Reindl W. Behrens A. Weiss S. Hüser N. Gerauer K. Ross R. Reske-Kunz A. B. Ahmad-Nejad P. Wagner H. Förster I. 2003Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. 97 5March 2003), 585-599.
Babuty D. Aupart M. Machet M. C. Rouchet S. Cosnay P. Garnier D. 1996Detection of acute cardiac allograft rejection with high resolution electrocardiography: experimental study in rats. , 15 11November 1996), 1120-1129.
Beer S. Scheikl T. Reis B. Hüser N. Pfeffer K. Holzmann B. 2005Impaired immune responses and prolonged allograft survival in Sly1 mutant mice. , 25 21November 2005), 9646-9660.
Billingham R. E. Krohn P. L. Medawar P. B. 1951Effect of cortisone on survival of skin homografts in rabbits. , 2 4739November 1951), 1157-1163.
Bishya R. H. 2011The “Mighty Mouse” Model in experimental cardiac transplantation. , 9 1e5.
Carrel A. Guthrie C. C. 1905Functions of transplanted Kidney. , 22 563(October 1905), 473.
Chapman J. R. O’Connell P. J. Nankivell B. J. 2005Chronic renal allograft dysfunction. 16 10October 2005), 3015-3026.
Chen Z. H. 1991A technique of cervical heterotopic heart transplantation in mice. Transplantation, 52 6December 1991), 1099-1101
Christie J. D. Edwards L. B. Kucheryavaya A. Y. Aurora P. Dobbels F. Kirk R. Rahmel A. O. Stehlik J. Hertz M. I. 2010The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. , 29 10October 2010), 1104-1118.
Colvin R. B. 2007Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. 18 4April 2007), 1046-1056.
Cornell L. D. Smith R. N. Colvin R. B. 2008Kidney transplantation: mechanisms of rejection and acceptance. , 3189-220.
Corry R. J. Winn H. J. Russell P. S. 1973Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. , 16 4October 1973), 343-350.
Doenst T. Schlensack C. Kobba J. L. Beyersdorf F. 2001A technique of heterotopic, infrarenal heart transplantation with double anastomosis in mice. , 20 7July 2001), 762-765.
Dooms H. Abbas A. K. 2006Control of CD4+ T-cell memory by cytokines and costimulators. 211June 2006), 23-38.
Evans R. Patzak I. Svensson L. De Filippo K. Jones K. McDowall A. Hogg N. 2009Integrins in immunity. , 122January 2009), 215-225.
Fulmer R. I. Cramer A. T. Liebelt R. A. Liebelt A. G. 1963Transplantation of cardiac tissue into the mouse ear. , 113September 1963), 273-285.
Hancock W. W. 2002Chemokines and transplant immunobiology. , 13 3March 2002), 821-824.
Hasegawa T. Visovatti S. H. Hyman M. C. Hayasaki T. Pinsky D. J. 2007Heterotopic vascularized murine cardiac transplantation to study graft arteriopathy. , 2 3471-480.
Hogg N. Laschinger M. Giles K. McDowall A. 2003T-cell integrins: more than just sticking points. , 116 23December 2003), 4695-4705.
Hüser N. Tertilt C. Gerauer K. Maier S. Traeger T. Assfalg V. Reiter R. Heidecke C. D. Pfeffer K. 2005CCR4-deficient mice show prolonged graft survival in a chronic cardiac transplant rejection model. , 35 1January 2005), 128-138.
Hüser N. Matevossian E. Schmidbauer P. Assfalg V. Scherberich J. E. Stangl M. Holzmann B. Friess H. Laschinger M. 2009Calculated withdrawal of low-dose immunosuppression based on a detailed immunological monitoring after kidney transplantation between monocygotic twins. 22 1-2(December 2009), 38-43.
Hüser N. Fasan A. Semmrich M. Schmidbauer P. Holzmann B. Laschinger M. 2010Intact LFA-1 deactivation promotes T-cell activation and rejection of cardiac allograft. , 22 1January 2010), 35-44.
Maier S. Tertilt C. Chambron N. Gerauer K. Huser N. Heidecke C. D. Pfeffer K. 2001Inhibition of natural killer cells results in acceptance of cardiac allografts inCD28−/− mice. , 7 5May 2001), 557-562.
Mao M. Liu X. Tian J. Yan S. Lu X. Gueler F. Haller H. Rong S. 2009A novel and knotless technique for heterotopic cardiac transplantation in mice. , 28 10(October 2009), 1102-1106.
Martins P. N. 2008Assessment of graft function in rodent models of heart transplantation. ., 28 7565-570.
Mestas J. Hughes C. C. 2004Of mice and not men: differences between mouse and human immunology. , 172 5March 2004), 2731-2738
Merrill J. P. Murray J. E. Harrison J. H. Guil W. R. 1956Successful homotransplantations of the human kidney between identical twins. , 160 4January 1956), 277-282.
Mottram P. L. Smith J. A. Mason A. Mirisklavos A. Dumble L. J. Clunie G. J. 1988Electrocardiographic monitoring of cardiac transplants in mice. , 22 5May 1988), 315-321.
Ono K. Lindsey E. S. 1969Improved technique of heart transplantation in rats. , 57 2February 1969), 225-229.
Sayegh M. H. Carpenter C. B. 2004Transplantation 50 years later- progress, challenges, and promises. , 351 26December 2004), 2678-2680.
Scherrer-Crosbie M. Glysing-Jensen T. Fry S. J. Vançon A. C. Gadiraju S. Picard M. H. Russell M. E. 2002Echocardiography improves detection of rejection after heterotopic mouse cardiac transplantation. , 15 10October 2002), 1315-1320.
Schmid C. Binder J. Heemann U. Tilney N. L. 1994Successful heterotopic heart transplantation in rat. , 15 4279-281.
Schnickel G. T. Whiting D. Hsieh G. R. Yun J. J. Fischbein M. P. Yao W. Shfizadeh A. Ardehali A. 2004CD8 lymphocytes are sufficient for the development of chronic rejection. , 78 11December 2004), 1634-1639.
Semmrich M. Smith A. Feterowski C. Beer S. Engelhardt B. Busch D. H. Bartsch B. Laschinger M. Hogg N. Pfeffer K. Holzmann B. 2005Importance of integrin LFA-1 deactivation for the generation of immune responses. , 201 12June 2005), 1987-1998.
Superina R. A. Peugh W. N. Wood K. J. Morris P. J. 1986Assessment of primarily vascularized cardiac allografts in mice. 42 2August 1986), 226-227.
Tan J. Zhou G. 2005Chemokine receptors and transplantation. , 2 5October 2005), 343-349.
Tomita Y. Zhang Q. W. Yoshikawa M. Uchida T. Nomoto K. Yasui H. 1997Improvd technique of heterotopic cervical heart transplantation in mice. , 64 11December 1997), 1598-1601.
Tong C. Li P. Wu N. L. Yan Y. Ying Q. L. 2010Production of p53 gene knockout rats by homologous recombination in embryonic stem cells. , 9 467September 2010), 211-213.
Wang Q. Liu Y. Li X. K. 2005Simplified technique for heterotopic vascularized cervical heart transplantation in mice. , 25 176-79.
Wang H. Arp J. Liu W. Faas S. J. Jiang J. Gies D. R. Ramcharran S. Garcia B. Zhong R. Rother R. P. 2007Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. , 179 7October 2007), 4451-4463.
Wehner J. R. Morrell C. N. Rodriguez E. R. Fairchild R. L. Baldwin W. M. 3rd. 29 6November 2009), 722-729.
Wu Y. J. Sato K. Ye Q. Ho C. 2004MRI investigations of graft rejection following organ transplantation using rodent models. , 38673-105.